Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
It was well documented that hypoxia-inducible factor-1α and fatty acid synthase were overexpressed in mammary gland carcinomas.
|
30950543 |
2019 |
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The enzyme fatty acid synthase (FASN) is highly expressed in many human carcinomas and its inhibition is cytotoxic to human cancer cells.
|
19189648 |
2009 |
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Overexpression of fatty acid synthase (FASN), the enzyme involved in the de novo synthesis of fatty acids, has been reported in several human carcinomas, including breast cancer, and has been related to poor prognosis.
|
23982110 |
2014 |
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Fatty acid synthase (FASN) is overexpressed in most human carcinomas, including non-small cell lung cancer (NSCLC), and contributes to poor prognosis.
|
31122252 |
2019 |
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
FASN, a nearly-universal druggable target in many human carcinomas and their precursor lesions, offers new therapeutic opportunities for metabolically treating and preventing cancer.
|
17882277 |
2007 |
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Both FAS mRNA and protein were significantly overexpressed in prostate carcinomas compared with the corresponding normal tissue.
|
12939396 |
2003 |
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
(-)-Epigallocatechin 3-gallate (EGCG) is a natural polyphenol from green tea with reported anticancer activity and capacity to inhibit the lipogenic enzyme fatty acid synthase (FASN), which is overexpressed in several human carcinomas.
|
29751678 |
2018 |
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Fatty acid synthase (FAS) has been shown previously to be highly expressed in breast and prostate carcinomas, but has low expression level in normal tissues.
|
17904792 |
2007 |
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We analyzed the expression of FASN and Ki-67, by immunohistochemistry on 29 carcinomas ex-pleomorphic adenoma (CXPAs) and 25 pleomorphic adenomas (PAs).
|
30597641 |
2019 |
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Several studies have demonstrated that fatty acid synthase (FAS) levels (protein and mRNA) are over expressed in many carcinomas.
|
23142364 |
2012 |
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
H-FABP-positive and H-FABP-negative carcinomas were analyzed for their clinicopathologic characteristics and FAS status.
|
15459486 |
2004 |
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Fatty acid synthase (FASN) expression and activity has emerged as a common phenotype in most human carcinomas, including breast cancer, and its expression is tightly linked to HER2 signaling pathways.
|
20973802 |
2010 |
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Fatty acid synthase expression associated with NAC1 is a potential therapeutic target in ovarian clear cell carcinomas.
|
22653145 |
2012 |
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
It now appears that human carcinomas and their pre-neoplastic lesions constitutively over express FAS and undergo significant endogenous fatty acid biosynthesis.
|
15577743 |
2005 |
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Recent studies showed that Fatty Acid Synthase (FASN), a lipogenic enzyme overexpressed in several carcinomas, plays an important role in drug resistance.
|
30875891 |
2019 |
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Expression of high levels of fatty acid synthase (FAS), an important enzyme in fatty acid synthesis, has been identified in a wide variety of human carcinomas.
|
9815604 |
1997 |